Resisting targeted therapy: fifty ways to leave your EGFR

Cancer Cell. 2011 Apr 12;19(4):437-40. doi: 10.1016/j.ccr.2011.03.020.

Abstract

Despite the promise of the new generation of molecularly targeted drugs, intrinsic and acquired resistance is proving to be as problematic as with cytotoxic drugs. Two recent papers have identified novel ways by which non-small cell lung cancers can exhibit resistance to EGFR inhibitors and suggest new therapeutic workarounds.

Publication types

  • Comment